menu search

ENVB / Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates
Enveric Biosciences (NASDAQ:ENVB) Inc announced that the company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family of novel molecules have been published by the World Intellectual Property Organization (WIPO). The Naples, Florida-based neuroscience company developing psychedelic-inspired mental health medicines said additional PCT patent applications are expected to be published over the coming months. Read More
Posted: Mar 15 2022, 08:57
Author Name: Proactive Investors
Views: 111050

ENVB News  

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

By InvestorPlace
May 18, 2023

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

Enveric Biosciences (NASDAQ: ENVB ) stock is enlivened amid an otherwise soft early afternoon session on Wall Street, delivering triple-digit percenta more_horizontal

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

By Business Wire
February 22, 2023

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the d more_horizontal

Enveric Biosciences to Present at the BIO CEO & Investor Conference

By Business Wire
February 1, 2023

Enveric Biosciences to Present at the BIO CEO & Investor Conference

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the more_horizontal

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during

By Business Wire
December 21, 2022

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the more_horizontal

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

By Proactive Investors
March 15, 2022

Enveric Biosciences touts the publication of four patent applications for psychedelic-inspired drug candidates

Enveric Biosciences (NASDAQ:ENVB) Inc announced that the company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family o more_horizontal

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

By Proactive Investors
March 1, 2022

Enveric Biosciences files portfolio of patent applications for tryptamine derivatives

Enveric Biosciences (NASDAQ:ENVB) announced that it has filed its tenth Patent Cooperation Treaty (PCT) application directed to tryptamine-based deriv more_horizontal


Search within

Pages Search Results: